Smithbridge Asset Management Inc. DE Invests $1.54 Million in Zoetis Inc. $ZTS

Posted by Kyle Jackson on Jul 2nd, 2026

Smithbridge Asset Management Inc. DE bought a new stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 13,059 shares of the company’s stock, valued at approximately $1,544,000.

A number of other hedge funds have also recently bought and sold shares of the company. Global Wealth Strategies & Associates acquired a new stake in Zoetis in the 4th quarter valued at about $25,000. Prosperity Bancshares Inc acquired a new position in shares of Zoetis in the 4th quarter worth approximately $25,000. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Zoetis in the 3rd quarter worth approximately $31,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis in the 4th quarter worth approximately $30,000. Finally, Elyxium Wealth LLC acquired a new stake in Zoetis during the fourth quarter valued at approximately $32,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other Zoetis news, Director Frank A. Damelio acquired 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael B. Mccallister bought 3,000 shares of the stock in a transaction on Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $72.48 on Thursday. The company has a 50-day moving average of $85.77 and a two-hundred day moving average of $109.95. The stock has a market cap of $30.39 billion, a price-to-earnings ratio of 12.02, a PEG ratio of 1.12 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a one year low of $71.47 and a one year high of $161.77.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the firm earned $1.48 EPS. The firm’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.87 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s payout ratio is currently 35.16%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Morgan Stanley reissued an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a research note on Friday, May 15th. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Finally, Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and an average target price of $126.92.

Get Our Latest Research Report on ZTS

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

Positive Sentiment: One recent note suggested Zoetis’ index shift could reinforce its competitive moat in companion-animal health, which supports the long-term investment case. Zoetis (ZTS) Index Shift: A Harbinger for Its Competitive Moat in Companion-Animal Health?
Neutral Sentiment: Barclays cut its price target on Zoetis to $85 from $136 and kept an equal-weight rating, signaling a more cautious valuation view but not a bearish downgrade. Barclays price target cut on Zoetis
Neutral Sentiment: TD Cowen lowered its target to $104 from $150 while maintaining a buy rating, reflecting softer near-term expectations while still seeing upside from current levels. TD Cowen price target cut on Zoetis
Neutral Sentiment: Multiple firms reminded investors about the July 27 deadline to join the Zoetis securities class action, keeping legal uncertainty in focus for shareholders. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action
Neutral Sentiment: Analyst commentary also highlighted that stabilization in Zoetis products may still be several quarters away, which adds to the view that fundamentals could remain challenged in the near term. This analyst thinks stabilization for Zoetis’ products could be several quarters away
Negative Sentiment: The series of class-action notices may raise investor concern about alleged misstatements tied to product adoption, adding a legal overhang to the shares. ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL

About Zoetis

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.